July 16th 2024
A recent study found that hormone therapy use in breast cancer patients aged 65 years and older is associated with a reduced risk of Alzheimer's and related dementias.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Aromatase inhibitors for climacteric symptoms in women with breast cancer
July 8th 2020New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.
Read More
Survival benefit in advanced or metastatic breast cancer with visceral metastases
June 12th 2020Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.
Read More
PD-L1 CNA as a biomarker in metastatic breast cancer
June 10th 2020Australian researchers believe that PD-L1 may have potential as an indicator of potential response to chemotherapy in women with metastatic breast cancer. That was based on results of a randomized trial, presented at the European Society for Medical Oncology in Lugano, Switzerland.
Read More
Vulvovaginal atrophy among breast cancer survivors
May 13th 2020A diagnosis of vulvovaginal atrophy (VVA) in breast cancer survivors is associated with a significant increase in the burden of illness and social costs, according to an Italian Delphi Panel in the journal Supportive Care in Cancer. These findings are primarily due to a rise in comorbidities and resource utilization, but adequate treatment might reduce the impact of the condition.
Read More
Is it cost-effective to do genetic testing on all women with breast cancer?
October 15th 2019While current guidelines recommend genetic testing in women with breast cancer who have relevant family history or clinical criteria, a new study examined whether it makes more sense to test all women with breast cancer.
Read More
USPSTF updates recommendations on medication use for breast cancer risk reduction
September 12th 2019The US Preventive Services Task Force (UPSTF) recently released an updated recommendation on medications for risk reduction of primary breast cancer and which patients would benefit most from a prescription.
Read More